产品
编 号：F161811
分子式：C25H22N6
分子量：406.48
分子式：C25H22N6
分子量：406.48
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1432597-26-6
产品详情
生物活性：
LDN-212854 is a bone morphogenetic protein (BMP) inhibitor that potently inhibits ALK2 (IC50: 1.3 nM). LDN-212854 also inhibits ALK1 (IC50: 2.40 nM). LDN-212854 can be used in the research of fibrodysplasia ossificans progressive and cancers, such as hepatocellular carcinoma (HCC).
体内研究：
LDN-212854 (intraperitoneal injection, 6 mg/kg, twice daily for 4 weeks) potently inhibits heterotopic ossification in an inducible transgenic mutant ALK2 mouse model of fibrodysplasia ossificans progressiva.LDN-212854 (intraperitoneal injection, 6 mg/kg, twice daily for 10-14 days) suppresses HCC tumor progression through repression of ID1 in HCC xenografts model.Animal Model:Murine inducible transgenic ALK2Q207D model of heterotopic ossification
Dosage:6 mg/kg
Administration:Intraperitoneal injection , twice daily for 4 weeks
Result:Prevented the formation of heterotopic bone and preserved limb range of motion with minimal or no impairment in the majority of mice.
Animal Model:HCC xenografts (Huh7 or MT cell)
Dosage:6 mg/kg
Administration:Intraperitoneal injection, twice daily for 10-14 days.
Result:Inhibited tumor growth and showed less spheroid/colony formation ability than PBS-treated tumor cells.
体外研究：
LDN-212854 (0-3.815 μM) blocks the phosphorylation of SMAD1/5/8 induced by BMP7 in BMPR2?/? cells.LDN-212854 (2.5 μM, 5 days ) inhibits cell proliferation in Huh7 and MT cells.LDN-212854 (0.5 μM, 48 h ) suppresses ID1 and EpCAM expression in Huh7 and MT cells.
LDN-212854 is a bone morphogenetic protein (BMP) inhibitor that potently inhibits ALK2 (IC50: 1.3 nM). LDN-212854 also inhibits ALK1 (IC50: 2.40 nM). LDN-212854 can be used in the research of fibrodysplasia ossificans progressive and cancers, such as hepatocellular carcinoma (HCC).
体内研究：
LDN-212854 (intraperitoneal injection, 6 mg/kg, twice daily for 4 weeks) potently inhibits heterotopic ossification in an inducible transgenic mutant ALK2 mouse model of fibrodysplasia ossificans progressiva.LDN-212854 (intraperitoneal injection, 6 mg/kg, twice daily for 10-14 days) suppresses HCC tumor progression through repression of ID1 in HCC xenografts model.Animal Model:Murine inducible transgenic ALK2Q207D model of heterotopic ossification
Dosage:6 mg/kg
Administration:Intraperitoneal injection , twice daily for 4 weeks
Result:Prevented the formation of heterotopic bone and preserved limb range of motion with minimal or no impairment in the majority of mice.
Animal Model:HCC xenografts (Huh7 or MT cell)
Dosage:6 mg/kg
Administration:Intraperitoneal injection, twice daily for 10-14 days.
Result:Inhibited tumor growth and showed less spheroid/colony formation ability than PBS-treated tumor cells.
体外研究：
LDN-212854 (0-3.815 μM) blocks the phosphorylation of SMAD1/5/8 induced by BMP7 in BMPR2?/? cells.LDN-212854 (2.5 μM, 5 days ) inhibits cell proliferation in Huh7 and MT cells.LDN-212854 (0.5 μM, 48 h ) suppresses ID1 and EpCAM expression in Huh7 and MT cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备